

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing of claims in the application.

1-13 (Cancelled)

14. (Currently amended) A compound capable of inhibiting activation of cytotoxic T lymphocytes and/or natural killer cells, ~~comprising an oligopeptide of at least 8 amino acids comprising the triad YYW (SEQ ID NO:1) and comprising a contiguous sequence of the sequence~~ said compound consisting of an oligopeptide of at least 8 amino acids, wherein said oligopeptide is within the amino acid sequence:

aa<sup>70</sup> aa<sup>71</sup> Q T aa<sup>74</sup> R aa<sup>76</sup> aa<sup>77</sup> L aa<sup>79</sup> aa<sup>80</sup> aa<sup>81</sup> aa<sup>82</sup> aa<sup>83</sup> Y Y W aa<sup>87</sup> aa<sup>88</sup> aa<sup>89</sup> aa<sup>90</sup> aa<sup>91</sup> (SEQ ID NO: 57).

wherein:

aa<sup>70</sup> is Q, H, S, N or K;

aa<sup>71</sup> is an aliphatic neutral amino acid;

aa<sup>74</sup> is D, Y or H;

aa<sup>76</sup> is E or V;

aa<sup>77</sup> is D, S or N;

aa<sup>79</sup> is R or G;

aa<sup>80</sup> is T, I, N or an aromatic amino acid;

aa<sup>81</sup> is an aliphatic non-polar amino acid;

aa<sup>82</sup> is R, L or an aromatic amino acid;

aa<sup>83</sup> is G or R;

aa<sup>87</sup> is any amino acid;

aa<sup>88</sup> is an aromatic amino acid or aliphatic amino acid of from 5 to 6 carbon atoms;

aa<sup>89</sup> is any amino acid;

aa<sup>90</sup> is any amino acid; and

aa<sup>91</sup> is any amino acid; and

wherein said oligopeptide includes the triad YYW (SEQ ID NO:1) of said sequence.

15. (Previously presented) The compound according to Claim 14, wherein said compound is of the formula:

R V/E N/D L R I A/L L R/E Y Y W Q/D S (SEQ ID NO:3)

wherein the backslashes intend that either amino acid may be present at that position.

16. (Previously presented) The compound according to Claim 15 which includes the sequence N L R I A L R Y Y W (SEQ ID NO:58).

17. (Previously presented) A compound comprising at least two oligopeptides according to Claim 14 joined at their C terminus to a polylysine.

18. (Previously presented) The compound of Claim 14, wherein said compound is a dimer of said oligopeptide.

19. (Previously presented) The compound of Claim 14, wherein at least one of said amino acids is the D-stereoisomer.